Targeting SphK2 Reverses Acquired Resistance of Regorafenib in Hepatocellular Carcinoma

Background: Regorafenib is a second-line therapy drug used for advanced hepatocellular carcinoma (HCC). Unfortunately, the survival benefit of the patients receiving this treatment is modest, which may be attributed to drug resistance. In the present study, sphingosine kinase 2 (SphK2) was targeted...

Full description

Saved in:
Bibliographic Details
Published in:Front Oncol
Main Authors: Shi, Weiwei, Zhang, Shan, Ma, Ding, Yan, Dongliang, Zhang, Guang, Cao, Yin, Wang, Zhongxia, Wu, Junhua, Jiang, Chunping
Format: Artigo
Language:Inglês
Published: Frontiers Media S.A. 2020
Subjects:
Oncology
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7327090/
https://ncbi.nlm.nih.gov/pubmed/32670862
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.00694
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items